Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial...

|About: Alnylam Pharmaceuticals, ... (ALNY)|By:, SA News Editor

Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial results for ALN-TTR02, a treatment for a genetic mutation of the transthyretin gene. The mutation causes a hereditary, systemic disease called ATTR, which can damage body organs and tissue such as the peripheral nerves and heart.